Capricor Therapeutics (CAPR) – Investment Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Capricor Therapeutics (NASDAQ: CAPR) recently:

• 8/14/2026 – Capricor Therapeutics was upgraded by Cantor Fitzgerald from “neutral” to “overweight”.
• 8/1/2026 – Capricor Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 7/31/2026 – Capricor Therapeutics was downgraded by JonesTrading from “buy” to “hold”.
• 7/30/2026 – Capricor Therapeutics was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $2.00 price target on the stock.
• 7/30/2026 – Capricor Therapeutics was downgraded by Maxim Group from “buy” to “hold”.
• 7/30/2026 – Capricor Therapeutics was downgraded by Cantor Fitzgerald from “overweight” to “neutral”. They now have a $3.50 price target on the stock.
• 7/30/2026 – Capricor Therapeutics was downgraded by LADENBURG THALM/SH SH from “buy” to “neutral”.
• 7/28/2026 – Capricor Therapeutics was downgraded by Alliance Global Partners from “buy” to “neutral”. They now have a $7.00 price target on the stock.
• 7/27/2026 – Capricor Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 7/27/2026 – Capricor Therapeutics had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 7/27/2026 – Capricor Therapeutics was downgraded by Roth Capital from “buy” to “neutral”. They now have a $7.00 price target on the stock.
• 7/27/2026 – Capricor Therapeutics was downgraded by B. Riley Financial, Inc. from “buy” to “neutral”. They now have a $10.00 price target on the stock.
• 6/25/2026 – Capricor Therapeutics was upgraded by LADENBURG THALM/SH SH to “strong-buy”.

Insider Activity

In other news, CFO Anthony Bergmann sold 24,100 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the completion of the transaction, the chief financial officer directly owned 11,223 shares in the company, valued at approximately $340,954.74. The trade was a 68.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 25,000 shares of company stock worth $759,158. 9.20% of the stock is currently owned by insiders.

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.